Full-Time

Director Medical Affairs

Immunology & Inflammation

Updated on 8/23/2026

Deadline 8/29/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

No salary listed

Berlin, Germany

In Person

Bachelor's

Category
Biology & Biotech (1)

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • Significant Medical Affairs leadership experience in pharma or biotech, with profound experience in the Immunology & Inflammation portfolio, including Dermatology, Rheumatology, and Gastroenterology, strongly preferred.
  • A medical degree or equivalent advanced scientific qualification is required.
  • A proven track record in evidence generation, scientific communication, stakeholder engagement, launch excellence, and lifecycle management is required.
  • Proven experience leading non-interventional studies, real-world evidence generation, study feasibility, site engagement, recruitment acceleration, and publication planning in a German Medical Affairs environment is required.
  • People-management experience, including direct team leadership, is mandatory.
  • Fluent business and medical English and native- or C1-level German are mandatory.
  • Strong scientific credibility and Medical Affairs expertise, with the ability to engage external experts confidently, are required.
  • Good understanding of clinical research, real-world evidence, medical governance, healthcare systems, and regulatory requirements is required.
  • Deep expertise in immune-mediated inflammatory diseases across Dermatology, Rheumatology, and Gastroenterology-relevant disease areas is required.
  • Strong understanding of German healthcare, access, regulatory, data privacy, pharmacovigilance, and compliance requirements relevant to Medical Affairs, clinical research, and evidence generation is required.
  • Comfort with digital and artificial-intelligence-enabled ways of working, including critical review of artificial-intelligence-generated outputs in a regulated setting, is required.
  • Strategic mindset, strong partnership and influencing abilities, sound judgment, accountability, and demonstrated people-leadership capabilities in coaching, talent development, performance management, succession planning, and team engagement are required.
Responsibilities
  • Define the multi-year Medical Affairs strategy for Pfizer’s Immunology & Inflammation portfolio in Germany, aligned with strategic, country, and global priorities.
  • Establish Immunology & Inflammation Medical Affairs as a trusted scientific voice and shape the medical impact narrative.
  • Drive scientific differentiation through evidence generation, medical storytelling, and stakeholder engagement.
  • Translate global medical priorities into local execution and generate actionable insights for medical and cross-functional decision-making.
  • Build trusted partnerships with healthcare professionals, key opinion leaders, patient organizations, professional societies, payers, policymakers, public-health institutions, digital-health stakeholders, and academic networks.
  • Shape the Immunology & Inflammation portfolio landscape in Germany by engaging healthcare decision-makers and translating healthcare-system needs and patient-journey gaps into medical priorities.
  • Own the Medical Plan and integrated evidence strategy, including generation, interpretation, and communication of real-world evidence, epidemiology, investigator-sponsored research, medical education, and publications.
  • Collaborate with International Medical, global medical, clinical development, health economics and outcomes research, access, and regulatory colleagues to align planning across markets.
  • Collaborate with GSSO on German clinical-study execution, including country outreach, study-site identification, and recruitment.
  • Use advanced analytics and artificial-intelligence-enabled insight synthesis to accelerate scientific impact, improve diagnosis rates and patient outcomes, and support healthcare-system decision-making.
  • Lead and oversee non-interventional studies and real-world evidence initiatives in Germany, including registries, study-design input, feasibility, site engagement, recruitment acceleration, protocol-related operational alignment, data interpretation, and publication planning.
  • Translate clinical-trial, real-world, and observational-study data into scientific narratives for external engagement, internal decision-making, access discussions, congress activities, abstracts, manuscripts, and medical education.
  • Provide medical and scientific support for market-access strategies and benefit dossiers, owning medical-evidence and scientific-narrative input and supporting data generation to address evidence gaps.
  • Lead Medical launch readiness across the innovative pipeline and indication extensions throughout the product lifecycle.
  • Build, develop, and inspire a high-performing Medical team across Medical Affairs and Field Medical.
  • Attract, retain, and grow scientific talent through succession planning and development, with substantial leadership time dedicated to coaching, feedback, and prioritization.
  • Drive alignment within the Medical Leadership Team to share capabilities and achieve joint success across therapeutic areas.
  • Champion responsible and compliant use of artificial intelligence with human oversight of generated outputs, and build AI fluency and scientific judgment across the team.
  • Simplify ways of working and eliminate low-value activities to maximize time for scientific exchange and patient impact.
  • Ensure compliance with legal, regulatory, and Pfizer policy requirements, including non-promotional boundaries, scientific integrity, pharmacovigilance, medical governance, and balanced scientific communication.
Desired Qualifications
  • Experience collaborating with clinical operations or GSSO on study-site identification, country outreach, or clinical-study recruitment.
  • Strong understanding of the German Immunology & Inflammation portfolio landscape, including stakeholders, policy, and access.
  • An established external scientific network with national key opinion leaders, academic centers, study sites, professional societies, and relevant healthcare stakeholders in Germany.
  • Experience driving responsible artificial-intelligence adoption and digital transformation in Medical Affairs to improve insight generation, evidence communication, operational efficiency, and team capability building in a regulated environment.
  • Demonstrated success leading complex matrix organizations and high-performing teams through transformation.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pfizer raised 2026 revenue guidance to $60.5-$62.5 billion on August 4, 2026.
  • Ex-COVID revenue grew 5% in Q2 2026, driven by Eliquis and Padcev.
  • FDA priority review for Talzenna-Xtandi targets a Q4 2026 approval decision.

What critics are saying

  • Eliquis loses U.S. exclusivity in 2028, threatening Pfizer’s biggest 2026 revenue engine.
  • Paxlovid fell 95% and Comirnaty dropped 34% in Pfizer’s second quarter 2026.
  • If Eliquis replacement and pipeline launches fail, Pfizer becomes a slow-decline cash distributor.

What makes Pfizer unique

  • Pfizer pairs Eliquis scale with oncology assets like Padcev and Talzenna in 2026.
  • Prevnar 20 won Québec public funding in May 2026, deepening vaccine franchise access.
  • Pfizer and Valneva’s Lyme vaccine moved into EMA review on August 14, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.

Yahoo Finance
Aug 18th, 2026
Two profitable stocks with solid fundamentals and one to ignore

Two companies leverage profitability to outpace competitors, whilst another faces headwinds, according to StockStory's analysis. Primoris, which builds and maintains infrastructure in utility, energy, and civil construction sectors, struggles with a low gross margin of 10.3% reflecting high production costs. The company has seen falling earnings per share over two years and weak free cash flow margin of 2.2% over five years. BrightSpring Health Services, offering home health care and pharmacy services, has posted 23.9% annual revenue growth over two years. Its revenue base of $14.37 billion provides economies of scale. Pfizer's massive $63.7 billion revenue base gives it significant negotiating power. The pharmaceutical giant's adjusted operating margin expanded by 18.5 percentage points over two years, whilst delivering a 17.5% return on capital.

Yahoo Finance
Aug 11th, 2026
Pfizer raises 2026 guidance to $62.5B, but boost relies on Eliquis facing patent expiry

Pfizer reported second-quarter revenue of $15 billion, up 3% year over year, and raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion. However, investors showed limited enthusiasm. The pharmaceutical giant's anticoagulant Eliquis, shared with Bristol Myers Squibb, generated $2.4 billion in quarterly revenue, up 21% year over year. The drug is now Pfizer's best-selling product. The concern is that Eliquis will lose patent exclusivity by the end of the decade. Pfizer's increased reliance on a drug facing imminent generic competition may signal it has yet to identify a suitable replacement. The company is expanding its pipeline, particularly in the GLP-1 market, where its candidate berobenatide is undergoing phase 3 trials after posting strong phase 2 results.

Yahoo Finance
Aug 11th, 2026
Pfizer raises guidance to $62.5B as BioNTech cuts forecast amid $928M loss

Pfizer and BioNTech reported contrasting second-quarter 2026 results as their post-pandemic strategies diverge. While the European Commission authorised their updated COVID-19 vaccine on 29 July, the former partners now face different financial realities. Pfizer posted revenues of $15 billion, up 1% operationally year-over-year. Excluding COVID products, revenue grew 5%, driven by strong performance from Eliquis, Padcev, and other non-COVID products. The company raised full-year revenue guidance by $500 million to $60.5–$62.5 billion and announced productivity initiatives expected to deliver $2.5 billion in additional savings between 2027 and 2029. BioNTech revenues fell 59.5% to €105.6 million as COVID vaccine demand declined. The company reported a net loss of €820.8 million and reduced full-year revenue guidance to €1.6–€1.9 billion. BioNTech maintains €16.6 billion in cash reserves.

Yahoo Finance
Aug 10th, 2026
Pfizer's earnings fall 58%, but dividend appears safe for now

Pfizer reported a 58% decline in net income for the first half of 2024, falling to $2.4 billion from $5.9 billion year-over-year. The decline was largely driven by $3.8 billion in non-cash impairment charges related to in-process research and development assets. Despite the earnings drop, the dividend appears sustainable. Over the past four quarters, Pfizer generated $11 billion in free cash flow, exceeding the approximately $9.8 billion paid in dividends. The company has struggled with growth whilst managing restructuring costs and integrating recent acquisitions. Its second quarter ended 30 June with a $248 million net loss. Pfizer's stock has fallen 44% over five years, though it's up 9% year-to-date. The dividend currently yields 6.4%.